1. Home
  2. Clinical Practice
  3. Cardiology
advertisement

Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
  • Overview

    This video brief features Dr. Lawrence Leiter reporting from AHA 2025 in New Orleans. He presents primary results from the landmark VESALIUS-CV trial, a large phase 3 study evaluating evolocumab, a PCSK9 inhibitor, in over 12,000 patients at high cardiovascular risk but without prior myocardial infarction or stroke. He outlines the trial design, key findings, and clinical relevance, emphasizing how these data may inform preventive strategies in this population. His overview also explores considerations for the real-world application of LDL-C-lowering therapies in primary cardiovascular prevention contexts. 

  • Provider(s)/Educational Partner(s)


    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

  • Commercial Support

    This activity is supported by an independent educational grant from Amgen, Inc.

Recommended
Details
Presenters
Related
  • Overview

    This video brief features Dr. Lawrence Leiter reporting from AHA 2025 in New Orleans. He presents primary results from the landmark VESALIUS-CV trial, a large phase 3 study evaluating evolocumab, a PCSK9 inhibitor, in over 12,000 patients at high cardiovascular risk but without prior myocardial infarction or stroke. He outlines the trial design, key findings, and clinical relevance, emphasizing how these data may inform preventive strategies in this population. His overview also explores considerations for the real-world application of LDL-C-lowering therapies in primary cardiovascular prevention contexts. 

  • Provider(s)/Educational Partner(s)


    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

  • Commercial Support

    This activity is supported by an independent educational grant from Amgen, Inc.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free